Stay updated with breaking news from Roger Adsett. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Insmed Incorporated (NASDAQ:INSM – Get Rating) has been given an average recommendation of “Buy” by the six research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price target among […]
Continued Progress Towards Optimizing Clinical Development Plans On Track to Initiate Phase 2b Study of Omilancor in Ulcerative Colitis Later this Year ...
Continued Progress Towards Optimizing Clinical Development Plans On Track to Initiate Phase 2b Study of Omilancor in Ulcerative Colitis Later this Year Completed Enrollment of Phase 1b Trial of... | March 24, 2022
INSM earnings call for the period ending September 30, 2021.